Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.43 |
| ▸ | ASPH | Q12797 | 11/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 10/20 | 0.43 |
| ▸ | RIOX2 | Q8IUF8 | 8/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 4/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425395 | 1.00 | KDM4E (0.43) | KDM4EASPHKDM8RIOX2MAPK1 | |
| SCHEMBL23673877 | 0.87 | MAP2K1 (0.37) | KDM4EDHODHMAPK14MAP2K1CSF1R | |
| SCHEMBL29425398 | 0.84 | MAPK14 (0.34) | KDM4EDHODHMAPK14MAP2K1CSF1R | |
| SCHEMBL30459905 | 0.84 | MAP2K1 (0.35) | KDM4EDHODHMAPK14MAP2K1CSF1R | |
| SCHEMBL29781364 | 0.84 | MAPK14 (0.34) | KDM4EDHODHMAPK14MAP2K1CSF1R | |
| SCHEMBL23673897 | 0.84 | MAPK14 (0.34) | KDM4EDHODHMAPK14MAP2K1CSF1R | |
| SCHEMBL23673990 | 0.84 | MAP2K1 (0.35) | KDM4EDHODHMAPK14MAP2K1CSF1R | |
| SCHEMBL23673873 | 0.83 | MAP2K1 (0.35) | KDM4EDHODHMAPK14MAP2K1CSF1R | |
| SCHEMBL24849417 | 0.83 | KDM4E (0.42) | KDM4EASPHKDM8RIOX2MAPK1 | |
| SCHEMBL29781342 | 0.81 | DHODH (0.48) | KDM4EL3MBTL1DHODHMAPK14MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725941-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20240327355-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-03 | — | — | US | disclosed |
| US-20240246922-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-25 | — | — | US | disclosed |
| EP-4375273-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-11964950-B2 | Arylamide derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-23 | — | — | US | disclosed |
| CN-117677607-A | Process for producing aryl amide derivative | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4186506-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-31 | — | — | EP | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| WO-2023003014-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | 中外製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021149776-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | 中外製薬株式会社 | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | BRAF, NRAS, KRAS | KDM4E 597/4885ASPH 2545/4885KDM8 802/4885 |
| US-20240246922-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, RAF1, NRAS | KDM4E 1751/4885ASPH 3615/4885KDM8 1725/4885 |
| US-11964950-B2 | Arylamide derivative having antitumor activity | BRAF, NRAS, KRAS | KDM4E 1541/4885ASPH 3671/4885KDM8 1427/4885 |
| US-20240327355-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | BRAF, RAF1, NRAS | KDM4E 205/4885ASPH 1932/4885KDM8 197/4885 |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, NRAS, KRAS | KDM4E 1507/4885ASPH 3738/4885KDM8 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.